This event is now closed, information is displayed here for information only.
The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017
but you can pre-register HERE to be advised when the programme is released
A one day meeting held on
Monday 19th September 2016
The Royal College of Physicians, London, UK
Chairs
![]() Professor of Interventional Oncology UCL Cancer Institute |
![]() Medical Oncology Consultant University College London Hospital |
From 08.00 | Registration & Coffee |
09.00 | Welcome / setting the scene: The Chairmen |
Morning Sessions: The Prostate SESSION 1: Early Detection & Diagnostics |
|
09.05 | Introduction from session Chair: Professor Mark Emberton |
09.10 | MRI in prostate cancer detection Dr Clare Allen Consultant Radiologist, UCLH, London, UK |
09.35 | Understanding biomarkers when diagnosing prostate cancer Dr Hayley Whitaker Head of the Centre for Molecular Intervention, UCL, London, UK |
10.00 | Biopsies in prostate cancer Dr Hashim Ahmed Reader in Surgical Uro-oncology, Research Department of Urology, UCL, London, UK |
10.25 | Discussion of merits and demerits of above findings Chairman & Speakers |
10.40 | Break |
SESSION 2: Multidisciplinary Team Educational Session | |
11.10 | Chair: Professor Mark Emberton |
Image based personalised active surveillance Dr Caroline Moore Senior Clinical Researcher & Honorary Consultant Urological Surgeon, UCL & UCLH, London, UK |
|
Tissue selective surgery Dr Hashim Ahmed Reader in Surgical Uro-oncology, Research Department of Urology, UCL, London, UK |
|
Tissue selective surgery Professor John Kelly Professor of Uro-Oncology, UCLH, London, UK |
|
Radiotherapy Dr Anita Mitra Consultant Clinical Oncologist, University College London Hospitals, London, UK |
|
12.10 | Keynote Presentation Reflections on diagnosis and treatment: Patients’ perspectives Professor Jan van der Meulen Professor of Clinical Epidemiology, London School of Hygiene & Tropical Medicine, London, UK |
12.30 | Lunch |
Afternoon Sessions: Beyond the Prostate SESSION 3: Metastatic Disease |
|
13.30 | Introduction from session Chair: Dr Mark Linch |
13.35 | Hormones Professor Heather Payne Consultant Clinical Oncologist, University College London Hospitals, London, UK |
14.00 | Chemotherapy Dr Ursula McGovern Consultant Medical Oncologist, University College London Hospitals, London, UK |
14.25 | Novel therapies Dr Mark Linch Consultant Medical Oncologist & Honorary Senior Lecturer, University College London Hospitals, London, UK |
14.50 | Discussion of merits and demerits of above findings Chairman & Presenters |
15.05 | Break |
15.35 | Keynote Presentation Opportunities for immunotherapies in urology Dr Sergio Quezada Group Leader – Immune Regulation and Tumor Immunotherapy Lab, UCL Cancer Institute, London, UK |
SESSION 4: Multidisciplinary Team Educational Session Management of Symptomatic Metastatic Prostate Cancer |
|
16.05 | Introduction from session Chair: Dr Mark Linch |
Radiotherapy Professor Heather Payne Consultant Clinical Oncologist, University College London Hospitals, London, UK |
|
Chemotherapy Dr Ursula McGovern Consultant Medical Oncologist, University College London Hospitals, London, UK |
|
EndoUrology Mr Daron Smith Consultant Urological Surgeon, University College London Hospitals, London, UK |
|
Palliative care Professor Paddy Stone Marie Curie Chair in Palliative and End of Life Care, University College London, UK |
|
Uro-Oncology CNS Janet Forgenie Uro-Oncology Clinical Nurse Specialist, University College London Hospitals, London, UK |
|
17.05 | Summary & Close |
This meeting is organised by:
and endorsed and supported by:


The Frontiers of Oncology 2019 meetings are supported by the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.